Amylyx Pharmaceuticals, Inc. is rebuilding after a major setback earlier this year when its sole commercial drug, Relyvrio (sodium phenylbutyrate/taurursodiol) for amyotrophic lateral sclerosis (ALS), was removed from the market due to lack of efficacy.
Key Takeaways
- Amylyx acquired the GLP-1 antagonist avexitide from Eiger, which it plans to move into Phase III testing for post-bariatric hypoglycemia early next year.
- Avexitide broadens the company’s pipeline outside of neurodegenerative disease for the first time
Now, the company has a new late-stage asset to focus on, a potential first-in-class glucagon-like peptide-1 (GLP-1) antagonist avexitide, acquired from Eiger BioPharmaceuticals, Inc. for around $35.1m. (Also see "Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens" - Scrip, 25 June, 2024.) The acquisition closed on 10 July and the company outlined development plans to investors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?